ALSO NOTED: Rosetta expands U.S. operations; DOV announces Phase I results; and much more...

> Rosetta Genomics is expanding its U.S. operations. Release

> DOV Pharmaceutical announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor for the treatment of depression and obesity. Release

> Pfizer is paring down its Ann Arbor campus. FiercePharma

> New insights into the way the brain operates are opening up a new therapeutic target to control fever as well as many of its symptoms like fatigue and loss of appetite. FierceBioResearcher

And Finally... J&J is suing the Red Cross. FiercePharma

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.